Royal DSM, Kensey Nash nearing U.S. antitrust approval
A $350 million tie-up of biotech firm Royal DSM and biomedical outfit Kensey Nash is understood to be in line for U.S. approval this week, with a deadline for regulatory questions...To view the full article, register now.
Already a subscriber? Click here to view full article